GEN-003 for Genital Herpes


GEN-003 is a Phase 3 ready, protein subunit T cell-enabled therapeutic vaccine intended to reduce the duration and severity of clinical symptoms associated with moderate-to-severe genital herpes, and to control transmission of the infection.

Created using our ATLAS platform, we designed GEN-003 to attack the genital herpes virus by inducing both a T cell and B cell (antibody) immune response via two antigens - ICP4 and gD2 – as well as a proprietary adjuvant Matrix-M™.

We have advanced GEN-003 successfully through Phase 2 development and are now seeking a partner for completion of clinical development and commercialization. Please contact us for more information.

GEN-003 Publications and Presentations